EPSILOGEN
8.7.2024 08:01:30 CEST | Business Wire | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).
Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”
About MOv18 IgE
MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.
About the Phase Ib study
The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hytera Advances AI-Powered Critical Communications at Global Partner Summit 202612.5.2026 14:41:00 CEST | Press release
Hytera Communications, a leading global provider of critical communications technologies and solutions, successfully concluded its annual Global Partner Summit (HGPS) 2026 on May 8 in Shanghai. Held under the theme “Advancing Together,” the summit brought together more than 500 attendees from over 60 countries to strengthen collaboration, share strategic insights, and explore future opportunities in AI-powered critical communications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512161109/en/ Yelin Jiang, CEO of Hytera Group, delivering the keynote speech at HGPS 2026 in Shanghai. Reflecting on Hytera’s development from 2025 to 2026, Yelin Jiang, CEO of Hytera Group, shared his outlook on the company’s future growth and innovation strategy. “Looking back on 2025, we grew in business and market, grew in technology, and grew together with our partners,” said Jiang. “Building on that momentum, we are now advancing together
NetApp Collaborates with Red Hat to Help Advance Data Protection and Scale for Red Hat OpenShift Deployments12.5.2026 14:00:00 CEST | Press release
New block-level change tracking capabilities enable faster backup and recovery for virtualized environments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced new NetApp data management capabilities optimized for Red Hat OpenShift that enable advanced levels of resilience and scale for virtualized environments, on-premises and in the cloud. The updates improve the speed and predictability of backup, recovery, and day-to-day operations so customers can migrate, scale, and manage virtual machine (VM) and container environments to enable innovation and agility with greater confidence. According to The state of virtualizationreport from Red Hat, 90 percent of organizations agree that virtualization supports innovation. Combined with the report’s finding that 71 percent of organizations have over half of their IT infrastructure virtualized, enterprises are expanding their virtualized environments to help them manage the increasing volumes of data that fuel
Telehouse Canada Undergoes Major Infrastructure Upgrade to Scale AI-Driven Organizations12.5.2026 14:00:00 CEST | Press release
With the introduction of direct liquid cooling, this first‑of‑its‑kind deployment within urban, interconnection‑rich data centre campuses in Canada establishes a new standard for enabling AI workloads. Telehouse Canada, a leading data centre service provider and subsidiary of KDDI Corporation, has announced the completion of a major infrastructure upgrade designed to support the next generation of AI‑driven workloads. By introducing direct liquid‑to‑chip technology, Telehouse enables high‑density AI inference deployments within its interconnection‑rich downtown Toronto data centre environments—reinforcing the company’s leadership in delivering resilient, future‑ready facilities that power Canada’s digital transformation and support the next wave of innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512456773/en/ Telehouse Canada's Advanced Cooling Framework As AI adoption accelerates across industries, organizatio
White Circle’s AI Control Platform Raises $11m from Industry Giants After Founder Goes Viral for Exposing Safety Flaw in Biggest AI Models12.5.2026 13:19:00 CEST | Press release
White Circle is the missing layer in AI, a single platform that lets companies monitor, secure and control everything their AI models do in real time Leaders from OpenAI, Anthropic, DeepMind, Hugging Face, Mistral and more, backed White Circle after its founder went viral for jailbreaking models with a single prompt With 1B+ API requests and counting, the enterprise-grade platform is already trusted by global names including Lovable, two of world’s largest digital banks and more to keep their AI accountable White Circle – the platform trusted by global brands to keep their AI models in check – has raised $11m from some of the biggest names in the industry including Romain Huet (OpenAI); Dirk Kingma (ex-OpenAI, now Anthropic); Guillaume Lample (Mistral); Thomas Wolf (Hugging Face); Olivier Pomel (Datadog); François Chollet (Keras); Mehdi Ghissassi (ex-DeepMind); Paige Bailey (DeepMind); and David Cramer (Sentry). The Seed funding will be used to further accelerate product development, e
Xylem Releases 2025 Sustainability Report12.5.2026 13:00:00 CEST | Press release
Highlights Measurable Progress on Global Water Challenges As global water challenges intensify, efficient and resilient water management is more critical than ever. Xylem (NYSE: XYL), a leader in global water solutions, has released its 2025 Sustainability Report, demonstrating how customer-driven innovation is transforming sustainability commitments into measurable performance outcomes for communities and the environment. Performance Highlights20 million people reached with access to clean water, sanitation, and hygiene since 2019 15% decrease in injury rate to 0.44 81% employee volunteer participation in 2025, up from 76% in 2023 16% reduction in Scope 1 and 2 (market-based) greenhouse gas emissions since 2023, progressing toward a 42% reduction target by 2030 15% improvement in water efficiency since 2023, progressing toward a 30% reduction goal by 2030 Xylem is globally recognized for sustainability, earning a place on the CDP Climate Change A List, recognition as one of TIME’s 10
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom